Gene therapy BB-301 shows promising early results for rare swallowing disorder

A one-time gene therapy is showing real promise for oculopharyngeal muscular dystrophy (OPMD), a rare inherited condition that progressively impairs swallowing. Benitec Biopharma's BB-301 uses a modified AAV9 vector to simultaneously silence the mutant PABPN1 gene responsible for OPMD and replace it with a healthy, functional copy — a dual-action approach the company calls "Silence and Replace." The therapy is injected directly into the swallowing muscles of the throat.

Interim phase 1b/2a data (NCT06185673) showed all 9 treated patients — 6 in the low-dose cohort and 3 in the high-dose cohort — met the trial's formal responder criteria, with no serious adverse events in either group. High-dose patients showed stronger early results on throat-emptying ability and a timed-drinking test compared to low-dose patients at the 3-month mark. Benitec plans to launch a pivotal study in mid-2027.

By the Numbers:

• 9 total patients treated (6 low-dose, 3 high-dose) — all met formal responder criteria
• High-dose vs. low-dose throat-emptying response at month 3: 100% vs. 67%
• High-dose vs. low-dose timed-drinking test response at month 3: 67% vs. 17%
• Sydney Swallow Questionnaire score improved 78% at 24 months in the first patient treated

Why it matters: OPMD has no approved disease-modifying treatments, leaving patients with a progressive and debilitating loss of swallowing function. If BB-301's early results hold in a larger pivotal trial, it could become the first gene therapy to address the root cause of this condition.